SIGN UP
LOG IN
I
INVA
Innoviva
18.63
0.46+2.53%After Hours: 18.63 0.00 0.00%16:20 08/01 EDT
OPEN/PREV CLOSE18.57/18.17
TODAY RANGE18.19-18.74
VOL984.24K
MARKET CAP1.17B
52 WEEK RANGE16.67-22.00
AVG VOL (3M)871.16K
% TURNOVER1.57%
TURNOVER--
P/E (TTM)-17.6204
% RANGE3.00%
EPS(TTM)-1.0573
P/E(FORWARD)15.02
P/B1.808
BVPS10.31
DIVIDEND--
P/S3.255
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.16B
SHARES OUTSTANDING62.78M
NEXT EARNINGS11/04-11/10
FREE FLOAT62.11M
LOT SIZE1
EX-DATE09/08/2015
News
Press Releases
Financial Reports
Profile
Simply Wall St·4d ago
Innoviva (NASDAQ:INVA) shareholders are still up 34% over 5 years despite pulling back 4.9% in the past week
NASDAQ·5d ago
Relative Strength Alert For Innoviva
Benzinga·07/14 12:14
This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Dow Jones·07/14 11:04
Innoviva Initiated at Buy by HC Wainwright & Co.
Dow Jones·07/14 11:04
Innoviva Price Target Announced at $40.00/Share by HC Wainwright & Co.
TipRanks·07/14 10:16
Innoviva initiated with a Buy at H.C. Wainwright
Dow Jones·07/11 12:12
Innoviva Initiated at Overweight by Cantor Fitzgerald
NASDAQ·06/23 19:44
First Week of August 15th Options Trading For Innoviva (INVA)
Simply Wall St·06/23 10:00
Innoviva, Inc.'s (NASDAQ:INVA) Low P/S No Reason For Excitement
TipRanks·06/12 11:20
Innoviva announces zoliflodacin NDA granted Priority Review by FDA
Seeking Alpha·06/10 14:36
Innoviva Specialty's gonorrhea antibiotic to undergo FDA review
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.